121 related articles for article (PubMed ID: 20705533)
21. Risk of invasive breast carcinoma among women diagnosed with ductal carcinoma in situ and lobular carcinoma in situ, 1988-2001.
Li CI; Malone KE; Saltzman BS; Daling JR
Cancer; 2006 May; 106(10):2104-12. PubMed ID: 16604564
[TBL] [Abstract][Full Text] [Related]
22. Breast cancer in Tunisia in 2004: a comparative clinical and epidemiological study.
Maalej M; Hentati D; Messai T; Kochbati L; El May A; Mrad K; Romdhane KB; Ben Abdallah M; Zouari B
Bull Cancer; 2008 Feb; 95(2):E5-9. PubMed ID: 18304901
[TBL] [Abstract][Full Text] [Related]
23. Important increase of invasive lobular breast cancer incidence in Geneva, Switzerland.
Verkooijen HM; Fioretta G; Vlastos G; Morabia A; Schubert H; Sappino AP; Pelte MF; Schäfer P; Kurtz J; Bouchardy C
Int J Cancer; 2003 May; 104(6):778-81. PubMed ID: 12640687
[TBL] [Abstract][Full Text] [Related]
24. Trends in breast cancer incidence associated with reductions in the use of hormone replacement therapy.
Silverman BG; Siegelmann-Danieli N; Braunstein R; Kokia ES
Cancer Epidemiol; 2011 Feb; 35(1):11-6. PubMed ID: 21163720
[TBL] [Abstract][Full Text] [Related]
25. [Receptor (ER, PgR) levels as prognostic factors in the endocrine therapy of pre- and post-menopausal patients with stage III infiltrative ductal and lobular cancer of the breast].
Calzada L; Salazar EL; Pedron Nuevo N
Ginecol Obstet Mex; 1996 Mar; 64():135-9. PubMed ID: 8729191
[TBL] [Abstract][Full Text] [Related]
26. Risk of recurrence after ductal carcinoma in situ of the breast.
Habel LA; Daling JR; Newcomb PA; Self SG; Porter PL; Stanford JL; Seidel K; Weiss NS
Cancer Epidemiol Biomarkers Prev; 1998 Aug; 7(8):689-96. PubMed ID: 9718221
[TBL] [Abstract][Full Text] [Related]
27. Use of menopausal hormone therapy and risk of ductal and lobular breast cancer among women 55-74 years of age.
Li CI; Daling JR; Haugen KL; Tang MT; Porter PL; Malone KE
Breast Cancer Res Treat; 2014 Jun; 145(2):481-9. PubMed ID: 24748570
[TBL] [Abstract][Full Text] [Related]
28. A French national survey on infiltrating breast cancer: analysis of clinico-pathological features and treatment modalities in 1159 patients.
Cutuli B; Cottu PH; Guastalla JP; Mechin H; Costa A; Jourdan R
Breast Cancer Res Treat; 2006 Jan; 95(1):55-64. PubMed ID: 16261401
[TBL] [Abstract][Full Text] [Related]
29. Regional variations in breast cancer incidence among California women, 1988-1997.
Reynolds P; Hurley SE; Quach AT; Rosen H; Von Behren J; Hertz A; Smith D
Cancer Causes Control; 2005 Mar; 16(2):139-50. PubMed ID: 15868455
[TBL] [Abstract][Full Text] [Related]
30. Comparison of age-specific incidence rate patterns for different histopathologic types of breast carcinoma.
Anderson WF; Chu KC; Chang S; Sherman ME
Cancer Epidemiol Biomarkers Prev; 2004 Jul; 13(7):1128-35. PubMed ID: 15247123
[TBL] [Abstract][Full Text] [Related]
31. Reduced risk of oestrogen receptor positive breast cancer among peri- and post-menopausal women in Scotland following a striking decrease in use of hormone replacement therapy.
Sharpe KH; McClements P; Clark DI; Collins J; Springbett A; Brewster DH
Eur J Cancer; 2010 Mar; 46(5):937-43. PubMed ID: 20122823
[TBL] [Abstract][Full Text] [Related]
32. [Epidemiological characterization and evolution of breast cancer patients in the Arica and Parinacota region in Chile, 1997-2007].
Caba F; Alvarado S; Cáceres DD
Rev Salud Publica (Bogota); 2011 Jun; 13(3):398-409. PubMed ID: 22030993
[TBL] [Abstract][Full Text] [Related]
33. Population-based hormone receptor-specific incidence trends of breast cancer in Germany.
Rusner C; Bandemer-Greulich U; Engel J; Stegmaier C; Zawinell A; Holleczek B; Katalinic A; Kuss O; Schmidt-Pokrzywniak A; Schubert-Fritschle G; Tillack A; Stang A
Maturitas; 2012 Oct; 73(2):152-7. PubMed ID: 22785007
[TBL] [Abstract][Full Text] [Related]
34. HRT and breast cancer: impact on population risk and incidence.
Coombs NJ; Taylor R; Wilcken N; Boyages J
Eur J Cancer; 2005 Aug; 41(12):1775-81. PubMed ID: 16087330
[TBL] [Abstract][Full Text] [Related]
35. Epidemiological survey of preinvasive breast cancer.
Vandenbroucke A; Bourdon C
Eur J Cancer Prev; 1993 Nov; 2 Suppl 3():3-10. PubMed ID: 8298449
[TBL] [Abstract][Full Text] [Related]
36. Breast cancer in south-east Republic of Yemen.
Abdul Hamid G; Tayeb MS; Bawazir AA
East Mediterr Health J; 2001 Nov; 7(6):1012-6. PubMed ID: 15332743
[TBL] [Abstract][Full Text] [Related]
37. Breast cancer incidence and menopausal hormone therapy in Norway from 2004 to 2009: a register-based cohort study.
Suhrke P; Zahl PH
Cancer Med; 2015 Aug; 4(8):1303-8. PubMed ID: 25991514
[TBL] [Abstract][Full Text] [Related]
38. Decline in breast cancer incidence after decrease in utilisation of hormone replacement therapy.
Katalinic A; Rawal R
Breast Cancer Res Treat; 2008 Feb; 107(3):427-30. PubMed ID: 17453336
[TBL] [Abstract][Full Text] [Related]
39. Age-specific incidence rates of in situ breast carcinomas by histologic type, 1980 to 2001.
Li CI; Daling JR; Malone KE
Cancer Epidemiol Biomarkers Prev; 2005 Apr; 14(4):1008-11. PubMed ID: 15824180
[TBL] [Abstract][Full Text] [Related]
40. Geographic excess of estrogen receptor-positive breast cancer.
Benz CC; Clarke CA; Moore DH
Cancer Epidemiol Biomarkers Prev; 2003 Dec; 12(12):1523-7. PubMed ID: 14693747
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
